Topotecan (HCl)

Overview

Topotecan (HCl) is intravenous antineoplastic (anticancer) agent. Topotecan, similar to irinotecan, is a derivative of camptothecin (CPT), a cytotoxic plant alkaloid isolated from the Chinese tree Camptotheca acuminata. it, along with irinotecan, is the first of a new class of antineoplastics, the topoisomerse I inhibitors. Topotecan is a second-line treatment for ovarian carcinoma. It has also been investigated for treatment of non-small-cell lung carcinoma, and for chronic myelomonocytic leukemia (CMML). As a single agent, topotecan offers equal response rates to other antineoplastics for lung or ovarian carcinomas. its role in combination therapy has not yet been well defined. Topotecan was FDA approved May 29, 1996 for the treatment of metastatic ovarian carcinoma.

Categories

• 8 Antineoplastics, immunomodulators and drugs used in palliative care
  • 8.2 Cytotoxic (anti-neoplastic) drugs

Page headings

Primary Characterstics

Indications

Pharmacokinetics

Contraindications

Topotecan (HCl) is contraindicated in conditions like Bone marrow depression.

Drug Interactions

Side Effects

Dosage

Topotecan (HCl)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
1.5 mg/sq.meter	3 (3)	24 hourly	IV Inf	Initially for 5 Days
1.5 mg/sq.meter	3 (3)	24 hourly	IV Inf	Maintenance for 21-Day Course
Paedriatic Dosage (20kg)
				Not recommended in this age group
Neonatal Dosage (3kg)
				Not recommended in this age group

High Risk Groups

Drug should not be given to Pregnant Mothers, and patients suffering from Liver Malfunction.

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Warning / Precautions

Storage Conditions

Interference in Pathology

Brands / Trade Names of Topotecan (HCl)

Manufacturers of Topotecan (HCl) in Pakistan

Back to top